# Daniel Bertholet

> Daniel Bertholet is a Series A investor at 4See Ventures backing Health Care and Biotechnology. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [4See Ventures](https://shizune.co/investors/profile/4see-ventures)
- Location: Geneva, Switzerland
- Total investments: 4
- Last investment: Aug 2015
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/daniel-bertholet-0b0638

Daniel Bertholet is an Investment Director in the Life Sciences practice at Endeavour Vision, with a focus on medtech investments. Daniel has invested in PneumRx, Symetis, CeQur, Nfocus (sold to Covidien), Endoart (sold to Allergan), Thommen Medical (exited), Neocutis (sold to Merz Pharma), Novalar Pharmaceuticals (exited) and Kuros Biosurgery. Healso participated in investments and/or follow-on investments in Native Networks (sold to Alcatel), eProject/Daptiv (exited), Paion (IPO), Nexx Systems (sold to Tokyo Electron) and Novimmune.Prior to his venture capital career, Daniel was the co-founder and CFO of a technology start-up and has invested as a business angel/private investor in private companies for over 15 years in Europe and the US. Daniel started his career as a consultant in country risk assessment for Business Environment Risk Intelligence (BERI) in the US and Switzerland.Daniel is a member of the Medtech Task Force of the European Venture Capital Association (EVCA) and has been on the Selection Committee of the Medtech Summits of the European Techtour in 2008, 2010, 2012, 2013 and on the Steering Committee of the OneMedForum conferences in the USA. Daniel has been asked to speak at industry events in US and Europe.Daniel holds an MBA with honours from the Institut d’Etudes Politiques in Paris and a MA in International Political Economy from the American University in Washington DC.Daniel is personally committed to support vulnerable children in Sub-Saharan Africa. He lives in Geneva with his wife and their three children.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 100% |
| Biotechnology | 3 | 75% |
| Medical | 2 | 50% |
| Medical Device | 2 | 50% |
| Beauty | 1 | 25% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 25% |
| Series C | 1 | 25% |
| Funding Round | 1 | 25% |
| Post-IPO Equity | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ReShape Lifesciences | ReShape Lifesciences is America's premier weight-loss solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical staplingprocedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. T | $38M | Post-IPO Equity | Aug 26, 2015 |  |
| PneumRx | PneumRx, Inc., a start-up medical device company, develops minimally invasive treatments for emphysema patients. The company develops RePneu Lung Volume Reduction Coil, an investigational device for treating emphysema patients. PneumRx, Inc. was founded in 2004 and is based in Mountain View, California. | $33M |  | Jan 04, 2011 |  |
| Nfocus Neuromedical | Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. Thecompany was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc. |  | Series C | Sep 13, 2010 |  |
| Neocutis | NEOCUTIS is dedicated to being the most admired, trusted and innovative physician-dispensed skincare brand. NEOCUTIS strives to fulfill this mission by developing exclusive technology platforms based on cutting-edge scientific research. Incorporating targeted technologies into luxurious product formulas enables NEOCUTIS to deliver innovativeskincare solutions that address key skincare concerns, including the signs of aging, discoloration, oxidative stress, skin redness and dryness. |  | Series A | Jun 15, 2004 |  |

4 of 4 investments shown.

## Co-investors
- [Adams Street Partners](https://shizune.co/investors/profile/adams-street-partners) — VC Fund, 1 deal together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 1 deal together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 1 deal together
- [Healthcor Management](https://shizune.co/investors/profile/healthcor-partners) — VC Fund, 1 deal together
- [New Leaf Venture Partners](https://shizune.co/investors/profile/new-leaf-venture-partners) — VC Fund, 1 deal together
- [Spray Venture Partners](https://shizune.co/investors/profile/spray-venture-partners) — VC Fund, 1 deal together

## About 4See Ventures

VC Fund · Secheron, Switzerland

4see ventures is a Swiss venture capital firm investing in exceptional entrepreneurs who are defining the future. We focus on real game-changers in their industries who are having a positive impact on society.

1 contacts available at 4See Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Daniel Bertholet | Founder and Managing Partner | https://shizune.co/investors/profile/daniel-bertholet |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Daniel Bertholet invest in?

Daniel Bertholet invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series C stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Daniel Bertholet last invest?

The most recent investment recorded for Daniel Bertholet closed in Aug 2015. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co